Zoetis Inc. stock slips 1.04% to $116.65, underperforming competitors

9 articles · Updated · MarketWatch · Apr 28

Zoetis shares ended Tuesday at $116.65, snapping a two-day winning streak amid a market downturn that saw the S&P 500 fall 0.49%.
The stock closed 32.27% below its 52-week high of $172.23, with trading volume at 3.0 million, below the 50-day average.
Zoetis underperformed peers like Merck, which fell 0.18%, and IDEXX Laboratories, which dropped 1.16%, during a broadly negative session for the stock market.

With its stock falling, why do analysts believe Zoetis is nearly 40% undervalued?

As competitors report key news, is market leader Zoetis beginning to lose its edge?

Can Zoetis's pipeline of 12 potential blockbusters overcome the market's current fears?

Beyond the stock price, what are the real safety concerns with this popular pet drug?

How will scrutiny on Librela impact the future of antibody treatments for pets?